A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• Patients must have schizophrenia that meets disease diagnostic criteria in DSM-IV-TR

• Patients must be inpatients during the study

• Patients must have a minimum total score of no less than 14 on the five items of the PANSS-EC and at least one individual item score of no less than 4 using the 1-7 scoring system prior to the first injection of study drug

Exclusion Criteria:

• Patients who have a known history of diabetes mellitus.

• Patients who have received treatment with antipsychotics or other prohibited concomitant medicines within 2 hours prior to the first IM study drug administration

• Patients who have had treatment with benzodiazepines within 4 hours prior to first IM study drug administration.